Niclosamide for Covid-19: bridging the gap

DOI record: { "DOI": "10.1007/s11033-021-06770-7", "ISSN": [ "0301-4851", "1573-4978" ], "URL": "http://dx.doi.org/10.1007/s11033-021-06770-7", "alternative-id": [ "6770" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "10 June 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "17 August 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "18 October 2021" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare that they have no competing interests." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Al-kuraishy", "given": "Hayder M.", "sequence": "first" }, { "affiliation": [], "family": "Al-Gareeb", "given": "Ali I.", "sequence": "additional" }, { "affiliation": [], "family": "Alzahrani", "given": "Khalid J.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2206-7236", "affiliation": [], "authenticated-orcid": false, "family": "Alexiou", "given": "Athanasios", "sequence": "additional" }, { "affiliation": [], "family": "Batiha", "given": "Gaber El-Saber", "sequence": "additional" } ], "container-title": "Molecular Biology Reports", "container-title-short": "Mol Biol Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 10, 19 ] ], "date-time": "2021-10-19T02:51:21Z", "timestamp": 1634611881000 }, "deposited": { "date-parts": [ [ 2023, 11, 11 ] ], "date-time": "2023-11-11T10:12:25Z", "timestamp": 1699697545000 }, "indexed": { "date-parts": [ [ 2024, 8, 27 ] ], "date-time": "2024-08-27T18:27:28Z", "timestamp": 1724783248541 }, "is-referenced-by-count": 49, "issue": "12", "issued": { "date-parts": [ [ 2021, 10, 18 ] ] }, "journal-issue": { "issue": "12", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 10, 18 ] ], "date-time": "2021-10-18T00:00:00Z", "timestamp": 1634515200000 } }, { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 10, 18 ] ], "date-time": "2021-10-18T00:00:00Z", "timestamp": 1634515200000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s11033-021-06770-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s11033-021-06770-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s11033-021-06770-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "8195-8202", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 10, 18 ] ] }, "published-online": { "date-parts": [ [ 2021, 10, 18 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.bcp.2021.114431", "author": "C Lugnier", "doi-asserted-by": "publisher", "first-page": "114431", "journal-title": "Biochem Pharmacol", "key": "6770_CR1", "unstructured": "Lugnier C, Al-Kuraishy HM, Rousseau E (2021) PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol 185:114431", "volume": "185", "year": "2021" }, { "author": "HM Al-Kuraishy", "first-page": "71", "journal-title": "Front Cardiovasc Med", "key": "6770_CR2", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Cruz-Martins N, Batiha GE (2021) Hyperbilirubinemia in Gilbert syndrome attenuates Covid-19 induced-metabolic disturbances: a case-report study. Front Cardiovasc Med 8:71", "volume": "8", "year": "2021" }, { "DOI": "10.4103/JMAU.JMAU_63_20", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "141", "issue": "4", "journal-title": "J Microsc Ultrastructure", "key": "6770_CR3", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Al-Buhadily AK, Al-Harchan NA, Lugnier C (2020) COVID-19 and phosphodiesterase enzyme type 5 inhibitors. J Microsc Ultrastructure 8(4):141", "volume": "8", "year": "2020" }, { "DOI": "10.4103/bbrj.bbrj_103_20", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "189", "issue": "3", "journal-title": "Biomed Biotechnol Res J", "key": "6770_CR4", "unstructured": "Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI (2020) Macrolides and COVID-19: an optimum premise. Biomed Biotechnol Res J 4(3):189", "volume": "4", "year": "2020" }, { "DOI": "10.4103/bbrj.bbrj_105_20", "author": "HM Al-Kuraishy", "doi-asserted-by": "crossref", "first-page": "33", "issue": "5", "journal-title": "Biomed Biotechnol Res J", "key": "6770_CR5", "unstructured": "Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Renin-Angiotensin system and fibrinolytic pathway in COVID-19: One-way skepticism. Biomed Biotechnol Res J 4(5):33", "volume": "4", "year": "2020" }, { "DOI": "10.1038/s43588-020-00007-6", "author": "G Galindez", "doi-asserted-by": "publisher", "first-page": "33", "issue": "1", "journal-title": "Nat Comput Sci", "key": "6770_CR6", "unstructured": "Galindez G, Matschinske J, Rose TD, Sadegh S, Salgado-Albarrán M, Späth J, Baumbach J, Pauling JK (2021) Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat Comput Sci 1(1):33–41", "volume": "1", "year": "2021" }, { "DOI": "10.1007/s40519-017-0373-1", "author": "AI Al-Gareeb", "doi-asserted-by": "publisher", "first-page": "339", "issue": "2", "journal-title": "Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity", "key": "6770_CR7", "unstructured": "Al-Gareeb AI, Aljubory KD, Alkuraishy HM (2017) Niclosamide as an anti-obesity drug: an experimental study. Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity 22(2):339–344", "volume": "22", "year": "2017" }, { "DOI": "10.1016/0163-7258(82)90064-X", "author": "P Andrews", "doi-asserted-by": "publisher", "first-page": "245", "issue": "2", "journal-title": "Bayluscide Pharmacol Ther", "key": "6770_CR8", "unstructured": "Andrews P, Thyssen J, Lorke D (1982) The biology and toxicology of molluscicides. Bayluscide Pharmacol Ther 19(2):245–295", "volume": "19", "year": "1982" }, { "key": "6770_CR9", "unstructured": "World Health Organization (2009) The selection and use of essential medicines: report of the WHO Expert Committee, March 2009 (including the 16th WHO model list of essential medicines and the 2nd WHO model list of essential medicines for children). World Health Organization, Geneva" }, { "DOI": "10.1016/j.cellsig.2017.04.001", "author": "W Chen", "doi-asserted-by": "publisher", "first-page": "89", "journal-title": "Cell Signal", "key": "6770_CR10", "unstructured": "Chen W, Mook RA Jr, Premont RT, Wang J (2018) Niclosamide: beyond an antihelminthic drug. Cell Signal 41:89–96", "volume": "41", "year": "2018" }, { "DOI": "10.1006/pest.1995.1049", "author": "OM AwAD", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Pestic Biochem Physiol", "key": "6770_CR11", "unstructured": "AwAD OM (1995) Assessment of the developmental toxicity of in utero exposure of Wistar albino rats to ametryne and Niclosamide. Pestic Biochem Physiol 53(1):1–9", "volume": "53", "year": "1995" }, { "DOI": "10.1371/journal.ppat.1002976", "author": "A Jurgeit", "doi-asserted-by": "publisher", "first-page": "e1002976", "issue": "10", "journal-title": "PLoS Pathog", "key": "6770_CR12", "unstructured": "Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF (2012) Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog 8(10):e1002976", "volume": "8", "year": "2012" }, { "DOI": "10.1016/j.antiviral.2016.10.003", "author": "YM Wang", "doi-asserted-by": "publisher", "first-page": "81", "journal-title": "Antiviral Res", "key": "6770_CR13", "unstructured": "Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC, Ho YJ (2016) Antiviral activities of Niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res 135:81–90", "volume": "135", "year": "2016" }, { "DOI": "10.1038/nm.4184", "author": "M Xu", "doi-asserted-by": "publisher", "first-page": "1101", "journal-title": "Nat Med", "key": "6770_CR14", "unstructured": "Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X et al (2016) Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 22:1101–1107", "volume": "22", "year": "2016" }, { "DOI": "10.1016/j.antiviral.2016.12.002", "author": "L Huang", "doi-asserted-by": "publisher", "first-page": "68", "journal-title": "Antiviral Res", "key": "6770_CR15", "unstructured": "Huang L, Yang M, Yuan Y, Li X, Kuang E (2017) Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation. Antiviral Res 138:68–78", "volume": "138", "year": "2017" }, { "DOI": "10.1371/journal.pntd.0006715", "author": "JC Kao", "doi-asserted-by": "publisher", "first-page": "6715", "issue": "8", "journal-title": "PLoS Negl Trop Dis", "key": "6770_CR16", "unstructured": "Kao JC, HuangFu WC, Tsai TT, Ho MR, Jhan MK, Shen TJ, Tseng PC, Wang YT, Lin CF (2018) The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. PLoS Negl Trop Dis 12(8):6715", "volume": "12", "year": "2018" }, { "DOI": "10.1128/AAC.00078-08", "author": "BE Korba", "doi-asserted-by": "publisher", "first-page": "4069", "issue": "11", "journal-title": "Antimicrob Agents Chemother", "key": "6770_CR17", "unstructured": "Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS (2008) Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 52(11):4069–4071", "volume": "52", "year": "2008" }, { "DOI": "10.1021/acsinfecdis.5b00030", "author": "PB Madrid", "doi-asserted-by": "publisher", "first-page": "317", "issue": "7", "journal-title": "ACS Infect Dis", "key": "6770_CR18", "unstructured": "Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 1(7):317–326", "volume": "1", "year": "2015" }, { "DOI": "10.1038/s41598-018-37290-3", "author": "JA Marrugal-Lorenzo", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Sci Rep", "key": "6770_CR19", "unstructured": "Marrugal-Lorenzo JA, Serna-Gallego A, Berastegui-Cabrera J, Pachón J, Sánchez-Céspedes J (2019) Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci Rep 9(1):1", "volume": "9", "year": "2019" }, { "DOI": "10.3390/life11080734", "author": "M Moubarak", "doi-asserted-by": "publisher", "first-page": "734", "issue": "8", "journal-title": "Life", "key": "6770_CR20", "unstructured": "Moubarak M, Kasozi KI, Hetta HF, Shaheen HM, Rauf A, Al-kuraishy HM et al (2021) The rise of SARS-CoV-2 variants and the role of convalescent plasma therapy for management of infections. Life 11(8):734", "volume": "11", "year": "2021" }, { "DOI": "10.3389/fcvm.2021.644095", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "644095", "journal-title": "Front Cardiovasc Med", "key": "6770_CR21", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Guerreiro SG, Cruz-Martins N, Batiha GE (2021) COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 8:644095", "volume": "8", "year": "2021" }, { "DOI": "10.1016/j.ajic.2005.12.006", "author": "J Yuan", "doi-asserted-by": "publisher", "first-page": "234", "issue": "4", "journal-title": "Am J Infect Control", "key": "6770_CR22", "unstructured": "Yuan J, Yun H, Lan W, Wang W, Sullivan SG, Jia S, Bittles AH (2006) A climatologic investigation of the SARS-CoV outbreak in Beijing, China. Am J Infect Control 34(4):234–236", "volume": "34", "year": "2006" }, { "DOI": "10.1016/j.idc.2019.08.001", "author": "EI Azhar", "doi-asserted-by": "publisher", "first-page": "891", "issue": "4", "journal-title": "Infect Dis Clin", "key": "6770_CR23", "unstructured": "Azhar EI, Hui DS, Memish ZA, Drosten C, Zumla A (2019) The middle east respiratory syndrome (MERS). Infect Dis Clin 33(4):891–905", "volume": "33", "year": "2019" }, { "DOI": "10.1128/AAC.48.7.2693-2696.2004", "author": "CJ Wu", "doi-asserted-by": "publisher", "first-page": "2693", "issue": "7", "journal-title": "Antimicrob Agents Chemother", "key": "6770_CR24", "unstructured": "Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, Liu CY, Huang HW, Chen SC, Hong CF, Lin RK (2004) Inhibition of severe acute respiratory syndrome coronavirus replication by Niclosamide. Antimicrob Agents Chemother 48(7):2693–2696", "volume": "48", "year": "2004" }, { "DOI": "10.1021/jm050184y", "author": "JJ Shie", "doi-asserted-by": "publisher", "first-page": "4469", "issue": "13", "journal-title": "J Med Chem", "key": "6770_CR25", "unstructured": "Shie JJ, Fang JM, Kuo CJ, Kuo TH, Liang PH, Huang HJ, Yang WB, Lin CH, Chen JL, Wu YT, Wong CH (2005) Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem 48(13):4469–4473", "volume": "48", "year": "2005" }, { "DOI": "10.1038/s41467-019-13659-4", "author": "NC Gassen", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Nat Commun", "key": "6770_CR26", "unstructured": "Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, Hafner K, Papies J, Mösbauer K, Zellner A, Zannas AS (2019) SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat Commun 10(1):1–6", "volume": "10", "year": "2019" }, { "DOI": "10.1016/j.pupt.2021.102008", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "102008", "journal-title": "Pulmonary Pharmacol Ther.", "key": "6770_CR27", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Cruz-Martins N, Batiha GE (2021) Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects. Pulmonary Pharmacol Ther. 67:102008", "volume": "67", "year": "2021" }, { "DOI": "10.33263/BRIAC106.72957328", "author": "D Romani", "doi-asserted-by": "publisher", "first-page": "7295", "journal-title": "Biointerface Res Appl Chem", "key": "6770_CR28", "unstructured": "Romani D, Noureddine O, Issaoui N, Brandán SA (2020) Properties and reactivities of Niclosamide in different media, a potential antiviral to treatment of COVID-19 by using DFT calculations and molecular docking. Biointerface Res Appl Chem 10:7295–7328", "volume": "10", "year": "2020" }, { "DOI": "10.26434/chemrxiv.12161493", "doi-asserted-by": "crossref", "key": "6770_CR29", "unstructured": "Guthappa R (2020) Molecular docking studies of N-acetyl cysteine, zinc acetyl cysteine and niclosamide on SARS Cov 2 protease and its comparison with hydroxychloroquine. Chemarxiv" }, { "DOI": "10.1021/acsinfecdis.0c00052", "author": "J Xu", "doi-asserted-by": "publisher", "first-page": "909", "issue": "5", "journal-title": "ACS Infect Dis", "key": "6770_CR30", "unstructured": "Xu J, Shi PY, Li H, Zhou J (2020) Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 6(5):909–915", "volume": "6", "year": "2020" }, { "DOI": "10.1128/AAC.00819-20", "author": "S Jeon", "doi-asserted-by": "publisher", "first-page": "e00819", "issue": "7", "journal-title": "Antimicrob Agents Chemother", "key": "6770_CR31", "unstructured": "Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 64(7):e00819-e820", "volume": "64", "year": "2020" }, { "DOI": "10.1371/journal.pone.0246803", "author": "AD Brunaugh", "doi-asserted-by": "publisher", "first-page": "e0246803", "issue": "2", "journal-title": "PLoS ONE", "key": "6770_CR32", "unstructured": "Brunaugh AD, Seo H, Warnken Z, Ding L, Seo SH, Smyth HD (2021) Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLoS ONE 16(2):e0246803", "volume": "16", "year": "2021" }, { "DOI": "10.33218/001c.18813", "author": "G Wang", "doi-asserted-by": "publisher", "first-page": "724", "issue": "1", "journal-title": "Precis Nanomed", "key": "6770_CR33", "unstructured": "Wang G, Gaikwad H, McCarthy M, Gonzalez-Juarrero M, Li Y, Armstrong M, Reisdorph N, Morrison T, Simberg D (2021) Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro. Precis Nanomed 4(1):724–737", "volume": "4", "year": "2021" }, { "DOI": "10.1101/2021.01.26.428293", "doi-asserted-by": "crossref", "key": "6770_CR34", "unstructured": "Jara MO, Warnken ZN, Sahakijpijarn S, Moon C, Maier EY, Christensen DJ, Koleng JJ, Peters JI, Hackman SD, Williams RO (2021) Niclosamide Inhalation powder made by thin-film freezing: pharmacokinetic and toxicology studies in rats and hamsters. bioRxiv" }, { "DOI": "10.1007/s00011-015-0801-5", "author": "L Liang", "doi-asserted-by": "publisher", "first-page": "225", "issue": "3", "journal-title": "Inflamm Res", "key": "6770_CR35", "unstructured": "Liang L, Huang M, Xiao Y, Zen S, Lao M, Zou Y, Shi M, Yang X, Xu H (2015) Inhibitory effects of Niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm Res 64(3):225–233", "volume": "64", "year": "2015" }, { "DOI": "10.1172/jci.insight.128414", "author": "I Cabrita", "doi-asserted-by": "publisher", "first-page": "e128414", "issue": "15", "journal-title": "JCI Insight", "key": "6770_CR36", "unstructured": "Cabrita I, Benedetto R, Schreiber R, Kunzelmann K (2019) Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight 4(15):e128414", "volume": "4", "year": "2019" }, { "DOI": "10.1021/acs.molpharmaceut.5b00098", "doi-asserted-by": "crossref", "key": "6770_CR37", "unstructured": "Costabile G, d’Angelo I, Rampioni G, Bondì R, Pompili B, Ascenzioni F, Mitidieri E, d’Emmanuele di Villa Bianca R, Sorrentino R, Miro A, Quaglia F (2015) Toward repositioning Niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology. Mol Pharm 12(8):2604–2617" }, { "DOI": "10.3892/mmr.2017.6768", "author": "LX Zhang", "doi-asserted-by": "publisher", "first-page": "1810", "issue": "2", "journal-title": "Mol Med Rep", "key": "6770_CR38", "unstructured": "Zhang LX, Zhao HJ, Sun DL, Gao SL, Zhang HM, Ding XG (2017) Niclosamide attenuates inflammatory cytokines via the autophagy pathway leading to improved outcomes in renal ischemia/reperfusion injury. Mol Med Rep 16(2):1810–1816", "volume": "16", "year": "2017" }, { "DOI": "10.1002/jmv.26232", "author": "B Hu", "doi-asserted-by": "publisher", "first-page": "250", "issue": "1", "journal-title": "J Med Virol", "key": "6770_CR39", "unstructured": "Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250–256", "volume": "93", "year": "2021" }, { "DOI": "10.1021/acs.jpclett.0c02677", "author": "A Mehranfar", "doi-asserted-by": "publisher", "first-page": "10284", "issue": "24", "journal-title": "J Phys Chem Lett", "key": "6770_CR40", "unstructured": "Mehranfar A, Izadyar M (2020) Theoretical design of functionalized gold nanoparticles as antiviral agents against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Phys Chem Lett 11(24):10284–10289", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.ejphar.2020.173438", "author": "CL Braga", "doi-asserted-by": "publisher", "first-page": "173438", "journal-title": "Eur J Pharmacol", "key": "6770_CR41", "unstructured": "Braga CL, Felix NS, Teixeira DE, Vieira JB, Silva-Aguiar RP, Bose RM, Antunes MA, de Novaes Rocha N, Caruso-Neves C, Cruz FF, Rocco PR (2020) Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. Eur J Pharmacol 887:173438", "volume": "887", "year": "2020" }, { "DOI": "10.1136/heartjnl-2020-317355", "author": "M Pagnesi", "doi-asserted-by": "publisher", "first-page": "1324", "issue": "17", "journal-title": "Heart", "key": "6770_CR42", "unstructured": "Pagnesi M, Baldetti L, Beneduce A, Calvo F, Gramegna M, Pazzanese V, Ingallina G, Napolano A, Finazzi R, Ruggeri A, Ajello S (2020) Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart 106(17):1324–1331", "volume": "106", "year": "2020" }, { "DOI": "10.3389/fnut.2021.649128", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "649128", "journal-title": "Front Nutr", "key": "6770_CR43", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Al-Maiahy TJ, Cruz-Martins N, Batiha GE (2021) The looming effects of estrogen in Covid-19: a rocky rollout. Front Nutr 8:649128", "volume": "8", "year": "2021" }, { "DOI": "10.1038/s41598-020-80010-z", "author": "Y Zuo", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Sci Rep", "key": "6770_CR44", "unstructured": "Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA (2021) Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 11(1):1–9", "volume": "11", "year": "2021" }, { "DOI": "10.1073/pnas.2010229117", "author": "S Kang", "doi-asserted-by": "publisher", "first-page": "22351", "issue": "36", "journal-title": "Proc Natl Acad Sci USA", "key": "6770_CR45", "unstructured": "Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H (2020) IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA 117(36):22351–22356", "volume": "117", "year": "2020" }, { "author": "LH Wang", "first-page": "1", "issue": "1", "journal-title": "Sci Rep", "key": "6770_CR46", "unstructured": "Wang LH, Xu M, Fu LQ, Chen XY, Yang F (2018) The antihelminthic Niclosamide inhibits cancer stemness, extracellular matrix remodeling, and metastasis through dysregulation of the nuclear β-catenin/c-Myc axis in OSCC. Sci Rep 8(1):1–3", "volume": "8", "year": "2018" }, { "DOI": "10.1038/s41598-019-47707-2", "author": "J Gyamfi", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Sci Rep", "key": "6770_CR47", "unstructured": "Gyamfi J, Lee YH, Min BS, Choi J (2019) Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis. Sci Rep 9(1):1–4", "volume": "9", "year": "2019" }, { "author": "HM Al-Kuraishy", "first-page": "1", "journal-title": "Mol Cell Biochem", "key": "6770_CR48", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Cruz-Martins N, Batiha GE (2021) The potential role of neopterin in Covid-19: a new perspective. Mol Cell Biochem 28:1–6", "volume": "28", "year": "2021" }, { "DOI": "10.1101/2020.04.15.997254", "doi-asserted-by": "crossref", "key": "6770_CR49", "unstructured": "Gassen NC, Papies J, Bajaj T, Dethloff F, Emanuel J, Weckmann K, Heinz DE, Heinemann N, Lennarz M, Richter A, Niemeyer D (2020) Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics. BioRxiv" }, { "DOI": "10.1016/j.bioorg.2020.104574", "author": "X He", "doi-asserted-by": "publisher", "first-page": "104574", "journal-title": "Bioorg Chem", "key": "6770_CR50", "unstructured": "He X, Li M, Ye W, Zhou W (2021) Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC). Bioorg Chem 107:104574", "volume": "107", "year": "2021" }, { "DOI": "10.3390/cancers10060178", "author": "R Aloni-Grinstein", "doi-asserted-by": "publisher", "first-page": "178", "issue": "6", "journal-title": "Cancers", "key": "6770_CR51", "unstructured": "Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V (2018) p53 and the viral connection: back into the future. Cancers 10(6):178", "volume": "10", "year": "2018" }, { "DOI": "10.4103/bbrj.bbrj_109_20", "author": "HM Al-Kuraishy", "doi-asserted-by": "crossref", "first-page": "101", "issue": "5", "journal-title": "Biomed Biotechnol Res J", "key": "6770_CR52", "unstructured": "Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Is ivermectin–azithromycin combination the next step for COVID-19? Biomed Biotechnol Res J 4(5):101", "volume": "4", "year": "2020" }, { "DOI": "10.3389/fmed.2021.644295", "author": "HM Al-Kuraishy", "doi-asserted-by": "publisher", "first-page": "110", "journal-title": "Front Med", "key": "6770_CR53", "unstructured": "Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Cruz-Martins N, Batiha GE (2021) COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin. Front Med 8:110", "volume": "8", "year": "2021" }, { "author": "N Hu", "first-page": "5426", "journal-title": "Toxicol Appl Pharmacol", "key": "6770_CR54", "unstructured": "Hu N, Fu Y, Li WF, Yang XR, Cao M, Li FF, Chen JH, Chen XY, Zhao H, Sun ZJ, Dong DL (2021) Chemical mitochondrial uncouplers share common inhibitory effect on NLRP3 inflammasome activation through inhibiting NFκB nuclear translocation. Toxicol Appl Pharmacol 21:5426", "volume": "21", "year": "2021" }, { "DOI": "10.1002/jmv.26397", "author": "M Ko", "doi-asserted-by": "publisher", "first-page": "1403", "issue": "3", "journal-title": "J Med Virol", "key": "6770_CR55", "unstructured": "Ko M, Jeon S, Ryu WS, Kim S (2021) Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol 93(3):1403–1408", "volume": "93", "year": "2021" }, { "DOI": "10.1186/s40064-016-3153-x", "author": "J Zhao", "doi-asserted-by": "publisher", "first-page": "1", "issue": "1", "journal-title": "Springerplus", "key": "6770_CR56", "unstructured": "Zhao J, He Q, Gong Z, Chen S, Cui L (2016) Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions. Springerplus 5(1):1–8", "volume": "5", "year": "2016" }, { "DOI": "10.1016/j.mehy.2020.110102", "author": "R Cecchini", "doi-asserted-by": "publisher", "first-page": "102", "journal-title": "Med Hypotheses", "key": "6770_CR57", "unstructured": "Cecchini R, Cecchini AL (2020) SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses 143:102", "volume": "143", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.04.479", "author": "M Montopoli", "doi-asserted-by": "publisher", "first-page": "1040", "issue": "8", "journal-title": "Ann Oncol", "key": "6770_CR58", "unstructured": "Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). Ann Oncol 31(8):1040–1045", "volume": "31", "year": "2020" }, { "DOI": "10.18632/oncotarget.8493", "author": "C Liu", "doi-asserted-by": "publisher", "first-page": "32210", "issue": "22", "journal-title": "Oncotarget", "key": "6770_CR59", "unstructured": "Liu C, Armstrong C, Zhu Y, Lou W, Gao AC (2016) Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget 7(22):32210", "volume": "7", "year": "2016" }, { "DOI": "10.1016/j.cellimm.2013.12.006", "author": "CS Wu", "doi-asserted-by": "publisher", "first-page": "15", "issue": "1–2", "journal-title": "Cell Immunol", "key": "6770_CR60", "unstructured": "Wu CS, Li YR, Chen JJ, Chen YC, Chu CL, Pan IH, Wu YS, Lin CC (2014) Antihelminthic Niclosamide modulates dendritic cells activation and function. Cell Immunol 288(1–2):15–23", "volume": "288", "year": "2014" }, { "DOI": "10.1093/biolre/ioaa010", "author": "N Sekulovski", "doi-asserted-by": "publisher", "first-page": "1011", "issue": "5", "journal-title": "Biol Reprod", "key": "6770_CR61", "unstructured": "Sekulovski N, Whorton AE, Tanaka T, Hirota Y, Shi M, MacLean JA, de Mola JR, Groesch K, Diaz-Sylvester P, Wilson T, Hayashi K (2020) Niclosamide suppresses macrophage-induced inflammation in endometriosis. Biol Reprod 102(5):1011–1019", "volume": "102", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-218048", "author": "P Ruscitti", "doi-asserted-by": "publisher", "first-page": "1152", "issue": "9", "journal-title": "Ann Rheum Dis", "key": "6770_CR62", "unstructured": "Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, Conforti A, Carubbi F, Di Cola I, Di Benedetto P, Cipriani P (2020) Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences. Ann Rheum Dis 79(9):1152–1155", "volume": "79", "year": "2020" }, { "DOI": "10.1101/2021.07.11.451951", "doi-asserted-by": "crossref", "key": "6770_CR63", "unstructured": "Garrett T, Coatsworth H, Mahmud I, Hamerly T, Stephenson CJ, Yazd H, Ayers JB, Miller M, Lednicky JA, Dinglasan RR (2021) Niclosamide reverses SARS-CoV-2 control of lipophagy. bioRxiv" }, { "DOI": "10.3390/ijms21072557", "author": "R Centeio", "doi-asserted-by": "publisher", "first-page": "2557", "issue": "7", "journal-title": "Int J Mol Sci", "key": "6770_CR64", "unstructured": "Centeio R, Cabrita I, Benedetto R, Talbi K, Ousingsawat J, Schreiber R, Sullivan JK, Kunzelmann K (2020) Pharmacological inhibition and activation of the Ca2+ activated Cl−channel TMEM16A. Int J Mol Sci 21(7):2557", "volume": "21", "year": "2020" }, { "DOI": "10.3389/fphar.2019.00051", "author": "K Miner", "doi-asserted-by": "publisher", "first-page": "51", "journal-title": "Front Pharmacol", "key": "6770_CR65", "unstructured": "Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, Elliott R, Chen JJ, Liu L, Leith A, Trueblood E (2019) Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol 10:51", "volume": "10", "year": "2019" }, { "DOI": "10.1038/cr.2017.88", "author": "Z Li", "doi-asserted-by": "publisher", "first-page": "1046", "issue": "8", "journal-title": "Cell Res", "key": "6770_CR66", "unstructured": "Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H (2017) Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res 27(8):1046–1064", "volume": "27", "year": "2017" }, { "DOI": "10.1016/j.tube.2019.04.008", "author": "X Fan", "doi-asserted-by": "publisher", "first-page": "S28", "journal-title": "Tuberculosis", "key": "6770_CR67", "unstructured": "Fan X, Xu J, Files M, Cirillo JD, Endsley JJ, Zhou J, Endsley MA (2019) Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). Tuberculosis 116:S28-33", "volume": "116", "year": "2019" }, { "DOI": "10.1101/2021.04.26.441457", "doi-asserted-by": "crossref", "key": "6770_CR68", "unstructured": "Weiss A, Touret F, Baronti C, Gilles M, Hoen B, Nougairède A, de Lamballerie X, Sommer MO (2021) Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B. 1.1. 7 and SA B. 1.351 variant. bioRxiv" }, { "DOI": "10.1080/14756366.2019.1690480", "author": "S Jo", "doi-asserted-by": "publisher", "first-page": "145", "issue": "1", "journal-title": "J Enzyme Inhib Med Chem", "key": "6770_CR69", "unstructured": "Jo S, Kim S, Shin DH, Kim MS (2020) Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 35(1):145–151", "volume": "35", "year": "2020" }, { "DOI": "10.1016/j.jphs.2021.05.004", "doi-asserted-by": "crossref", "key": "6770_CR70", "unstructured": "Johnson TO, Adegboyega AE, Iwaloye O, Eseola OA, Plass W, Afolabi B, Rotimi D, Ahmed EI, Albrakati A, Batiha GE, Adeyemi OS (2021) Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2. J Pharmacol Sci" }, { "DOI": "10.1016/j.bbrc.2017.01.140", "author": "L Chen", "doi-asserted-by": "publisher", "first-page": "416", "issue": "2", "journal-title": "Biochem Biophys Res Commun", "key": "6770_CR71", "unstructured": "Chen L, Wang L, Shen H, Lin H, Li D (2017) Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition. Biochem Biophys Res Commun 484(2):416–421", "volume": "484", "year": "2017" }, { "DOI": "10.1016/j.heliyon.2020.e04050", "author": "N Niyomdecha", "doi-asserted-by": "publisher", "first-page": "e04050", "issue": "6", "journal-title": "Heliyon", "key": "6770_CR72", "unstructured": "Niyomdecha N, Suptawiwat O, Boonarkart C, Jitobaom K, Auewarakul P (2020) Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition. Heliyon 6(6):e04050", "volume": "6", "year": "2020" }, { "DOI": "10.1038/s41577-021-00536-9", "author": "A Bonaventura", "doi-asserted-by": "publisher", "first-page": "319", "issue": "5", "journal-title": "Nat Rev Immunol", "key": "6770_CR73", "unstructured": "Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A (2021) Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 21(5):319–329", "volume": "21", "year": "2021" }, { "author": "S Engin", "first-page": "1", "journal-title": "Cardiovasc Toxicol", "key": "6770_CR74", "unstructured": "Engin S, Yasar YK, Barut EN, Sezen SF (2021) Improved endothelium-dependent relaxation of thoracic aorta in niclosamide-treated diabetic rats. Cardiovasc Toxicol 27:1–9", "volume": "27", "year": "2021" }, { "key": "6770_CR75", "unstructured": "Laubscher GJ, Lourens PJ, Venter C, Grobbelaar LM, Kell DB, Pretorius E (2021) A decision-tree approach to treat platelet hyperactivity and anomalous blood clotting in acute COVID-19 patients. medRxiv" }, { "author": "G Hamilton", "first-page": "142", "journal-title": "Oncomedicine", "key": "6770_CR76", "unstructured": "Hamilton G, Rath B (2017) Repurposing of anthelminthics as anticancer drugs. Oncomedicine 2:142–149", "volume": "2", "year": "2017" }, { "DOI": "10.1002/cbin.10915", "author": "R Ke", "doi-asserted-by": "publisher", "first-page": "384", "issue": "4", "journal-title": "Cell Biol Int", "key": "6770_CR77", "unstructured": "Ke R, Xu Q, Li C, Luo L, Huang D (2018) Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism. Cell Biol Int 42(4):384–392", "volume": "42", "year": "2018" } ], "reference-count": 77, "references-count": 77, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s11033-021-06770-7" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Niclosamide for Covid-19: bridging the gap", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "48" }